Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4

Eduardo Pauls, Ester Ballana, Gemma Moncunill, Margarida Bof́ill, Bonaventura Clotet, Cristina Ramo-Tello, José A. Esté

Research output: Contribution to journalArticleResearchpeer-review

13 Citations (Scopus)

Abstract

The alpha4beta7 integrin has been shown to serve as a coreceptor for HIV. One anti-alpha4 integrin agent (natalizumab) has been approved for the treatment of multiple sclerosis and Crohn's disease. We found that activation of CD4 + T cells with retinoic acid induced the upregulation of alpha4 and beta7 integrins. However, natalizumab failed to block the replication of HIV-1 strains in lymphoid MT-4 cells or CD4 + T cells at concentrations up to 125 μg/ml. Our results suggest that alpha4 integrins are not essential cofactors for HIV replication.
Original languageEnglish
Pages (from-to)266-268
JournalAIDS
Volume23
Issue number2
DOIs
Publication statusPublished - 14 Jan 2009

Fingerprint Dive into the research topics of 'Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4'. Together they form a unique fingerprint.

  • Cite this

    Pauls, E., Ballana, E., Moncunill, G., Bof́ill, M., Clotet, B., Ramo-Tello, C., & Esté, J. A. (2009). Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4. AIDS, 23(2), 266-268. https://doi.org/10.1097/QAD.0b013e328320a7f8